{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/check?name=Bell%20International%20Laboratories%2C%20Inc.","name":"Bell International Laboratories, Inc.","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-10-04T19:05:12.831Z"},"count":1,"matches":[{"id":"e4e0b66d29f038c1","posted_date":"2024-03-05","letter_issue_date":"2024-02-15","company_name":"Bell International Laboratories, Inc.","issuing_office":"Division of Pharmaceutical Quality Operations III","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/e4e0b66d29f038c1"}]}